SV BR1 GM breast cancer vaccine companion diagnostic - Briacell Therapeutics

Drug Profile

SV BR1 GM breast cancer vaccine companion diagnostic - Briacell Therapeutics

Alternative Names: BriaDx™; BriaVax™ companion diagnostic - briacell; BriaVax™ DX -Briacell

Latest Information Update: 02 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BriaCell Therapeutics Corp
  • Class Cancer vaccines; Gene therapies; Immunotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 29 Nov 2016 BriaCell Therapeutics files for patent protection with the US Patent and Trademark Office for SV BR1 GM breast cancer vaccine companion diagnostic in USA
  • 14 Sep 2015 Preclinical trials in Breast cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top